Occurrence of sectoral @entity432 and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for XXXX .

@entity1 @entity2194 @entity5066 @entity64 @entity455 @entity5 @entity3538 @entity941 @entity989 @entity432 @entity732 @entity995
BACKGROUND: Superselective ophthalmic artery chemotherapy (SOAC) has recently been proposed as an alternative to intravenous chemoreduction for @entity995 . Preliminary results appear promising in terms of @entity5 control and eye conservation, but little is known regarding @entity2194 and visual prognosis. In this study, we report on the vascular adverse effects observed in our initial cohort of 13 @entity1 . METHODS: The charts of 13 consecutive @entity1 with @entity995 who received a total of 30 injections (up to 3 injections of a single agent per @entity1 at 3-week interval) of melphalan (0.35 mg/kg) in the ophthalmic artery between November 2008 and June 2010 were retrospectively reviewed. RetCam fundus photography and @entity941 angiography were performed at presentation and before each injection. Vision was assessed at the latest visit. RESULTS: Enucleation and external beam radiotherapy could be avoided in all cases but one, with a mean follow-up of 7 months. Sectoral @entity432 leading to @entity5066 was observed temporally in 2 eyes (15%) 3 weeks to 6 weeks after the beginning of @entity989 in 1 eye 2 weeks after injection. There was no @entity64 or other clinically significant systemic side effects except a perioperative transient @entity3538 in one @entity1 . Vision ranged between 20/1600 and 20/32 depending on the status of the macula. CONCLUSION: Superselective ophthalmic artery chemotherapy was effective in all @entity1 with no @entity64 or other @entity455 . Unlike intravenous chemoreduction, SOAC is associated with potentially sight-threatening adverse effects, such as severe @entity5066 secondary to subacute @entity732 , not to mention the risk of ophthalmic @entity432 , which was not observed in this series. Further analysis of the risks and benefits of SOAC will define its role within the therapeutic arsenal. Meanwhile, we suggest that SOAC should be given in one eye only and restricted to advanced cases of @entity995 , as an alternative to enucleation and/or external beam radiotherapy.
